![]() |
Perjeta® (pertuzumab) first treatment for advanced breast cancer to extend surviv
Perjeta, in combination with Herceptin® (trastuzumab) and chemotherapy (docetaxel), can extend survival in women with previously untreated, advanced HER2-positive breast cancer to over four and...
More... |
| All times are GMT -7. The time now is 04:50 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021